2016
DOI: 10.3389/fphar.2016.00283
|View full text |Cite
|
Sign up to set email alerts
|

Exercise-Induced Release of Pharmacologically Active Substances and Their Relevance for Therapy of Hepatic Injury

Abstract: Chronic liver disease (CLD) features constant parenchymal injury and repair together with an increasing hepatic impairment, finally leading to fibrosis and cirrhosis and a heightened risk of hepatocellular carcinoma (HCC). Closely related to the rise in obesity, the worldwide prevalence of nonalcoholic fatty liver disease, the most common form of CLD, has reached an epidemic dimension and is estimated to afflict up to 46% of the general population, including more than one out of three U.S. citizens. Up to now th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
16
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
9

Relationship

3
6

Authors

Journals

citations
Cited by 13 publications
(16 citation statements)
references
References 165 publications
0
16
0
Order By: Relevance
“…In the general population, NAFLD is estimated to afflict up to 30% of the general population in the Western countries and is in most cases provoked by physical inactivity and excessive calorie intake 102 . In particular, NAFLD occurs in middle-aged subjects in association with obesity, hyperglycemia, dyslipidemia, and type 2 diabetes.…”
Section: Existing and Emerging Therapies For Hepatic Fibrosismentioning
confidence: 99%
See 1 more Smart Citation
“…In the general population, NAFLD is estimated to afflict up to 30% of the general population in the Western countries and is in most cases provoked by physical inactivity and excessive calorie intake 102 . In particular, NAFLD occurs in middle-aged subjects in association with obesity, hyperglycemia, dyslipidemia, and type 2 diabetes.…”
Section: Existing and Emerging Therapies For Hepatic Fibrosismentioning
confidence: 99%
“…Currently, other pharmacotherapeutics for NAFLD and NASH such as GR-MD-02, which binds to the carbohydrate-binding domain of galectin-3, which is upregulated in cases of liver fibrosis and has an essential function in cell–cell interactions, angiogenesis, apoptosis, and macrophage activation, are also under investigation 115 . Beside these pharmaceutical treatment options, weight loss induced by lifestyle changes and controlled exercise have outstanding value in the treatment of fatty liver disease 102 . This was impressively demonstrated in a prospective study of 293 patients with histologically proven NASH, in which effective lifestyle changes to reduce weight over 52 weeks improved histologic features associated with NASH 116 .…”
Section: Existing and Emerging Therapies For Hepatic Fibrosismentioning
confidence: 99%
“…Exercise acts as an important role on bone metabolic disorders in addition to pharmaceutical treatment. Besides mechanical interaction, it could remold bone tissue through regulating the expression of many factors such as tumor necrosis factor (1). Irisin is one of them and has attracted much attention since its discovery.…”
Section: Introductionmentioning
confidence: 99%
“…However, a liver biopsy should be performed based on an individualized decision and is still the gold standard in scoring and grading of steatosis, inflammation, and fibrosis [12]. Although an ultimate therapy is still missing, beneficial effects on NAFLD/NASH progression are energy restriction, lifestyle changes, improved diets, and elevated physical activity [13]. In addition, in biopsy-proven NASH and fibrosis, medication with antiglycemic drugs, insulin sensitizers, synbiotics, or compounds interfering with fat metabolism or preventing oxidative stress have favorable effects on disease outcome [13,14].…”
Section: Figurementioning
confidence: 99%